Srinivas Akkaraju - 19 Feb 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: MLYS
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 19:47:10 UTC
Prior SEC filing: 13 Jan 2026
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

Srinivas Akkaraju filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 20 Feb 2026.

Key facts

This page summarizes Srinivas Akkaraju's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 19:47.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001253170 Primary reporting owner

AKKARAJU SRINIVAS

Relationship: Director, 10%+ Owner
Address: 628 MIDDLEFIELD ROAD, PALO ALTO
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Award

Transaction value: $0
Shares: +6,200
Change %
Price: $0.000000
Shares after: 6,200
Date: 19 Feb 2026
Ownership: Direct
Footnotes: F1

MLYS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,871,018
Date: 19 Feb 2026
Ownership: See footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLYS transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +8,300
Change %
Price: $0.000000
Shares after: 8,300
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,300
Exercise price: $28.06
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.

Footnote F2

Of this amount, 588,235 shares are directly held by Samsara Opportunity Fund, L.P. (Samsara Opp LP). Samsara Opportunity Fund GP, LLC (Samsara Opp GP) is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. Also, of this amount, 5,282,783 shares are directly held by Samsara BioCapital L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

Footnote F3

The stock option vests in 12 substantially equal monthly installments following the date of grant.